Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
6.26
+0.25 (4.16%)
At close: Apr 7, 2026, 4:00 PM EDT
6.38
+0.12 (1.92%)
After-hours: Apr 7, 2026, 5:26 PM EDT
Precision BioSciences Employees
Precision BioSciences had 68 employees as of December 31, 2025. The number of employees decreased by 40 or -37.04% compared to the previous year.
Employees
68
Change (1Y)
-40
Growth (1Y)
-37.04%
Revenue / Employee
$503,882
Profits / Employee
-$672,412
Market Cap
161.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 68 | -40 | -37.04% |
| Dec 31, 2024 | 108 | -1 | -0.92% |
| Dec 31, 2023 | 109 | -89 | -44.95% |
| Dec 31, 2022 | 198 | 0 | - |
| Dec 31, 2021 | 198 | -33 | -14.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Molecular Partners AG | 134 |
| Heron Therapeutics | 128 |
| Cibus | 118 |
| Immunic | 92 |
| Agenus | 81 |
| Cartesian Therapeutics | 75 |
| Connect Biopharma Holdings | 62 |
DTIL News
- 26 days ago - Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - Business Wire
- 27 days ago - Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - Business Wire
- 4 weeks ago - Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 - Business Wire
- 4 weeks ago - Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - Business Wire
- 4 weeks ago - Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event - Business Wire
- 5 weeks ago - Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire
- 6 weeks ago - Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
- 7 weeks ago - Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy - Business Wire